Analysts have lowered their expectations for UnitedHealth (UNH) after the company provided weak guidance for 2026. Despite beating Q4 earnings estimates narrowly, the projected full-year revenue of $439 billion is significantly lower than Wall Street’s expectations, signaling a potential first annual revenue decline in over three decades. Major firms like Mizuho and Truist have reduced their price targets on UNH, although they maintain their Outperform and Buy ratings, citing a slower-than-expected earnings recovery.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Analysts Lower Expectations for UnitedHealth (UNH) Following Weak Guidance
Analysts have lowered their expectations for UnitedHealth (UNH) after the company provided weak guidance for 2026. Despite beating Q4 earnings estimates narrowly, the projected full-year revenue of $439 billion is significantly lower than Wall Street’s expectations, signaling a potential first annual revenue decline in over three decades. Major firms like Mizuho and Truist have reduced their price targets on UNH, although they maintain their Outperform and Buy ratings, citing a slower-than-expected earnings recovery.